2021
Fibrinogen/Albumin Ratio as a Promising Marker for Predicting Survival in Pancreatic Neuroendocrine Neoplasms
Deng S, Fan Z, Xia H, Gong Y, Qian Y, Huang Q, Cheng H, Jin K, Xiao Z, Luo G, Yu X, Liu C. Fibrinogen/Albumin Ratio as a Promising Marker for Predicting Survival in Pancreatic Neuroendocrine Neoplasms. Cancer Management And Research 2021, 13: 107-115. PMID: 33447083, PMCID: PMC7802789, DOI: 10.2147/cmar.s275173.Peer-Reviewed Original ResearchProgression-free survivalFibrinogen/albumin ratioIndependent risk factorOverall survivalPoor OSPan-NENsCutoff valuePrognostic valueMultivariate analysisAssociated with poor OSRisk factorsGrade 3 tumorsStage IV tumorsOptimal cutoff valuePancreatic neuroendocrine neoplasmsNonfunctioning tumorsIV tumorsNeuroendocrine neoplasmsPrimary endpointSecondary endpointsPredictive biomarkersClinicopathological characteristicsPredicting prognosisUnivariate analysisPredicting survival
2019
The CRP/Albumin Ratio Predicts Survival And Monitors Chemotherapeutic Effectiveness In Patients With Advanced Pancreatic Cancer
Fan Z, Fan K, Gong Y, Huang Q, Yang C, Cheng H, Jin K, Ni Q, Yu X, Luo G, Liu C. The CRP/Albumin Ratio Predicts Survival And Monitors Chemotherapeutic Effectiveness In Patients With Advanced Pancreatic Cancer. Cancer Management And Research 2019, 11: 8781-8788. PMID: 31632137, PMCID: PMC6778322, DOI: 10.2147/cmar.s211363.Peer-Reviewed Original ResearchCut-off valueOverall survivalMultivariate analysisPredictor of overall survivalOptimal cut-off valueAdvanced pancreatic cancer patientsPrognostic value of baselineKaplan-Meier survival curvesMonitoring chemotherapeutic effectsAdvanced pancreatic cancerSurvival of patientsNinety-five patientsEfficacy of chemotherapyLog-rank testIndicator of prognosisPancreatic cancer patientsCox proportional hazards modelsEffects of chemotherapyValue of baselineProportional hazards modelMetastatic adenocarcinomaPrimary endpointPrognostic valuePancreatic cancerPredicting survival
2017
The metastasis status and tumor burden-associated CA125 level combined with the CD4/CD8 ratio predicts the prognosis of patients with advanced pancreatic cancer: A new scoring system
Yang C, Cheng H, Luo G, Lu Y, Guo M, Jin K, Wang Z, Yu X, Liu C. The metastasis status and tumor burden-associated CA125 level combined with the CD4/CD8 ratio predicts the prognosis of patients with advanced pancreatic cancer: A new scoring system. European Journal Of Surgical Oncology 2017, 43: 2112-2118. PMID: 28802662, DOI: 10.1016/j.ejso.2017.07.010.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkers, TumorCA-125 AntigenCarcinoma, Pancreatic DuctalCD4 Lymphocyte CountCD8-Positive T-LymphocytesFemaleFlow CytometryHumansMaleMiddle AgedNeoplasm MetastasisNeoplasm StagingPancreatic NeoplasmsPredictive Value of TestsPrognosisRetrospective StudiesSurvival RateTumor BurdenConceptsCD4/CD8 ratioNew scoring systemAdvanced pancreatic cancerCD8 ratioPrognosis of patientsCA125 levelsPancreatic cancerScoring systemPrognostic valueHigher CD4/CD8 ratioMultivariate analysisAdvanced pancreatic cancer patientsComplete clinical dataHigher CA125 levelsKaplan-Meier methodIndependent prognostic factorPancreatic cancer patientsLog-rank testTumor immune responseCox hazard modelPrognostic factorsCancer patientsMetastasis statusClinical dataImmune response